Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of "traditional" cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.

Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status / Bellati, Filippo; Visconti, Valeria; Napoletano, Chiara; Antonilli, Morena; Frati, Luigi; BENEDETTI PANICI, Pierluigi; Nuti, Marianna. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - STAMPA. - 9:4(2009), pp. 541-565. [10.2174/156800909788486722]

Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status

BELLATI, FILIPPO;VISCONTI, Valeria;NAPOLETANO, Chiara;ANTONILLI, Morena;FRATI, Luigi;BENEDETTI PANICI, PIERLUIGI;NUTI, Marianna
2009

Abstract

Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of "traditional" cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.
2009
gynecological cancer; immune response; immune signatures; prognostic indicators; taa
01 Pubblicazione su rivista::01a Articolo in rivista
Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status / Bellati, Filippo; Visconti, Valeria; Napoletano, Chiara; Antonilli, Morena; Frati, Luigi; BENEDETTI PANICI, Pierluigi; Nuti, Marianna. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - STAMPA. - 9:4(2009), pp. 541-565. [10.2174/156800909788486722]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/224598
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact